忍者ブログ
Informative and Instructive Science News
[6]  [7]  [8]  [9]  [10]  [11]  [12]  [13]  [14]  [15]  [16
×

[PR]上記の広告は3ヶ月以上新規記事投稿のないブログに表示されています。新しい記事を書く事で広告が消えます。

Looking at the Sun Can Trigger a Sneeze

For some people, bright lights mean big sneezes

full-sneeze-of-woman 
PHOTIC SNEEZE: Crossed nerve signals in the brain may be the reason some people sneeze when exposed to a sudden bright light.

Have you ever emerged from a matinee movie, squinted into the sudden burst of sunlight and sneezed uncontrollably? Up to a third of the population will answer this question with an emphatic "Yes!" (whereas nearly everyone else scratches their head in confusion). Sneezing as the result of being exposed to a bright light—known as the photic sneeze reflex—is a genetic quirk that is still unexplained by science, even though it has intrigued some of history's greatest minds.

Aristotle mused about why one sneezes more after looking at the sun in The Book of Problems: "Why does the heat of the sun provoke sneezing?" He surmised that the heat of the sun on the nose was probably responsible.

Some 2 ,000 years later, in the early 17th century, English philosopher Francis Bacon neatly refuted that idea by stepping into the sun with his eyes closed—the heat was still there, but the sneeze was not (a compact demonstration of the fledgling scientific method). Bacon's best guess was that the sun's light made the eyes water, and then that moisture ("braine humour," literally) seeped into and irritated the nose.

Humours aside, Bacon's moisture hypothesis seemed quite reasonable until our modern understanding of physiology made it clear that the sneeze happens too quickly after light exposure to be the result of the comparatively sluggish tear ducts. So neurology steps in: Most experts now agree that crossed wires in the brain are probably responsible for the photic sneeze reflex.

A sneeze is usually triggered by an irritation in the nose, which is sensed by the trigeminal nerve, a cranial nerve responsible for facial sensation and motor control. This nerve is in close proximity to the optic nerve, which senses, for example, a sudden flood of light entering the retina. As the optic nerve fires to signal the brain to constrict the pupils, the theory goes, some of the electrical signal is sensed by the trigeminal nerve and mistaken by the brain as an irritant in the nose. Hence, a sneeze.

But because this harmless (albeit potentially embarrassing) phenomenon doesn't seem to be linked with any other medical condition, scientific study of the subject has been scarce. Research has done little more than document its existence and attempt to gauge its prevalence. No rigorous studies exist, but informal surveys peg 10 to 35 percent of the population as photic sneezers. A study in the 1960s showed that the trait is autosomal-dominant—the gene is neither on the X nor Y chromosome and only one copy of the gene has to be present for the trait to be expressed—so if one parent sneezes when they look at a bright light, about half of his or her children will, too.

The genetic culprit remains unidentified, but scientists are starting to take an interest in trying to find out. "I think it's worth doing," says Louis Ptácek, a neurologist at the University of California, San Francisco, and an investigator at the Howard Hughes Medical Institute. Ptácek studies episodic disorders such as epilepsy and migraine headaches, and he believes that investigating the photic sneeze reflex could shed light on their related neurology.

Epileptic seizures are sometimes triggered by flashing lights and migraine headaches are often accompanied by photophobia. "If we could find a gene that causes photic sneezing, we could study that gene and we might learn something about the visual pathway and some of these other reflex phenomena," Ptácek says.

But until he and his colleagues find the right families for their study, the photic sneeze reflex will remain something of a genetic novelty act, like the ability to roll your tongue. Although a 1993 paper in the journal Military Medicine raised concerns that light-induced sneezing might endanger fighter pilots, for whom a split second of lost vision could be lethal in certain situations, such fear was largely put to rest when a small study found that wearing sunglasses eliminated the effect.

Beyond that blip of gravitas, papers published about photic sneezing have largely leaned toward the whimsical end of the spectrum. Consider one 1978 publication that took advantage of the then-raging acronym fad and suggested an alternate name for the photic sneeze reflex: Autosomal-dominant Compelling Helio-Ophthalmic Outburst syndrome, or, of course, ACHOO.

PR

New Diet Drug in Battle of the Bulge

Early research shows that taranabant helps to suppress appetite and burn fat.

fat-guy-eating-burger 
FAT CHANCE: A new drug designed to curb appetite is on the horizon.

Want to lose weight but lack the willpower to just say no to fatty foods and sweets? Help may be on the way. The first clinical trials of an experimental weight-loss drug show that it helps curb appetite—and burn more fat—even at low doses.

Researchers report in the journal Cell Metabolism that taranabant, developed by drug giant Merck, is the second drug found to be successful in fighting flab by blocking cannabinoid receptors (responsible for the psychological effects of marijuana a.k.a. Cannabis sativa) in the brain's reward circuitry.

"The effects of marijuana on appetite have been known for millennia from its medicinal and recreational use," said study author Steven Heymsfield of Merck Research Laboratories. "The ingredient responsible stimulates cannabinoid receptors. When you block the cannabinoid system with an antagonist like taranabant, you suppress appetite."

The first indication that the cannabinoid-1 (CB1) receptor might be a prime weight-loss target came during studies of an earlier drug called rimonabant (manufactured by sanofi-aventis), which is now available as a diet aid in several European countries but has yet to receive the Food and Drug Administration's nod for use in the U.S.

Heymsfield and his team found that obese people given low doses of taranabant consumed fewer calories, expended more energy and shed pounds. The scientists initially tested the drug on animals, which lost weight on doses that inhibited just 30 percent of their cannabinoid receptors. Armed with this knowledge, the researchers used positron emission tomography (PET) imaging to determine the amount (four to six milligrams) of taranabant that would achieve a similar goal in humans.

They found that obese patients lost significant weight during the 12-week trial at surprisingly low doses ranging from 0.5 to six milligrams; those who took a 12-milligram dose consumed 27 percent fewer calories than subjects given a placebo. The researchers reported that plump participants on the drug also expended more energy while at rest and appeared to burn more fat.

But lest you think more is less—literally—take note: The medical team said higher doses had some potential negative side effects, most notably nausea, vomiting and moodiness. This was not entirely unexpected, Heymsfield said, given that it has the opposite effect of marijuana, which has been known to quell nausea associated with cancer treatments and, also, to calm rather than irritate people.

Next up: A larger phase III clinical trial to further explore the drug's potential benefits and risks. "All we have here is 12 weeks," Heymsfield said. "We don't yet know what will happen at six months or a year.

Cell Defenses and the Sunshine Vitamin

Scientists now recognize that vitamin D does much more than build strong bones and that many people are not getting enough of it. Is widespread D deficiency contributing to major illnesses?

 

Graphic - Key Concepts

  • Vitamin D, long associated only with its role in bone formation, is actually active throughout the human body, powerfully influencing immune system responses and cell defenses.
  • It can be obtained from food or manufactured by human skin exposed to sunlight. Measures of vitamin D levels show, however, that many people have too little of it circulating in their blood to protect health.
  • Clear associations between low vitamin D levels and cancers, autoimmunity, infectious diseases and other conditions suggest that current daily intake recommendations for this critical nutrient need revision.

    It was called the sunshine cure, and in the early 20th century, before the era of antibiotics, it was the only effective therapy for tuberculosis known. No one knew why it worked, just that TB patients sent to rest in sunny locales were often restored to health. The same “treatment” had been discovered in 1822 for another historic scourge, rickets—a deforming childhood condition caused by an inability to make hardened bone. Rickets had been on the rise in 18th- and 19th-century Europe, coinciding with industrialization and the movement of people from the countryside to the polluted cities, when a Warsaw doctor observed that the problem was relatively rare in rural Polish children. He began experimenting with city children and found that he could cure their rickets with exposure to sunshine alone.

By 1824 German scientists found that cod-liver oil also had excellent antirickets properties, although that treatment did not catch on widely, in part because the possibility that a food might contain unseen micronutrients important to health was not yet understood by doctors. And nearly a century would pass before scientists made the connection between such dietary cures for rickets and the beneficial effects of sunshine. Early 20th-century researchers showed that irradiated skin, when fed to rats with artificially induced rickets, had the same curative properties as cod-liver oil. The critical common element in the skin and the oil was finally identified in 1922 and dubbed vitamin D. By then the idea of “vital amines,” or vitamins, was a popular new scientific topic, and subsequent research into the functions of vitamin D in the body was very much shaped by D’s image as one of those essential micronutrients that humans can obtain only from food.

The association with rickets also steered most vitamin D research for the next 50 years toward understanding the molecule’s role in bone building and how it acts in the kidneys, intestines and the skeleton itself to help control the flow of calcium into and out of bones from the bloodstream. In the past quarter century, however, studies of vitamin D’s function have broadened, revealing that the so-called sunshine vitamin does far more than build bones. Extensive evidence now shows that D has potent anticancer actions and also serves as an important regulator of immune system responses. Moreover, many of D’s newly recognized benefits are maximized when it is present in the bloodstream at levels considerably higher than those found in many populations. These findings, together with epidemiological data linking low vitamin D levels to disease, support the possibility that widespread vitamin D deficiency is contributing to a number of serious illnesses.

A Versatile Switch
To make sense of new findings about vitamin D, it pays to first review what D actually is and how it is used in the human body. People can obtain the molecule known as vitamin D from limited food sources, such as fatty fish and fish oil, and, today, from dietary supplements. But we can also make it ourselves, through a chemical reaction that happens in the skin when it is exposed to ultraviolet B (UVB) light. Strictly speaking, then, vitamin D is not a vitamin at all, because with moderate UVB exposure, we do not need to get it from food. In temperate regions of the world, however, UVB light is insufficient to induce adequate vitamin D synthesis in the skin for up to six months of the year, and then dietary sources of vitamin D become essential.

The term “vitamin D” generally refers collectively to the two very similar molecules that come from each of those sources. Vitamin D3, which is also known as cholecalciferol, is created by skin cells called keratinocytes from a breakdown product of cholesterol, 7-dehydrocholesterol, in response to UVB light. Vitamin D2, or ergocalciferol, is derived from a similar plant sterol, and the resulting molecule has slight structural differences that distinguish it from D3. Neither version has any biological activity in the body, however. First, either molecule must be modified by a series of related enzymes in a process called hydroxylation, which adds two thirds of a water molecule to generate 25-hydroxyvitamin D (25D).

That conversion takes place primarily in the liver, but various cell types within the skin are also capable of performing the transformation locally. The 25D made by the liver is nonetheless the major form of vitamin D circulating in the bloodstream. When it is needed in the body, a final conversion to the biologically active form is required­—25D is further hydroxylated and becomes 1,25-dihydroxyvitamin D (1,25D). The enzyme that performs this task, 1alpha-hydroxylase, was first discovered in the kidney, and renal processing is responsible for generating much of the body’s circulating 1,25D supply.

Once again, however, scientists now realize that many other tissues, including cells of the immune system and the skin, can also make that enzyme and perform the 25D conversion themselves. Skin is therefore unique among organs in that it is capable of manufacturing biologically active 1,25D in the presence of UVB light from start to finish, although local production of 1,25D from circulating 25D in other tissues is a substantial source of vitamin D’s biological activity in the body that was not appreciated until very recently. Once the breadth of D’s activity is considered, though, it becomes easy to see why the ability to make its active form for local use might be important to certain types of cells.

The 1,25D molecule functions as a switch that can turn genes “on” or “off” in virtually every tissue in the human body. This form of D acts by attaching to a protein known as the vitamin D receptor (VDR), which serves as a so-called transcription factor inside a cell’s nucleus. Once bound by 1,25D, the VDR protein seeks out a companion protein, the retinoid-x receptor (RXR), and the complex they form binds to a specific region of the cell’s DNA adjacent to a target gene. Their attachment to the DNA induces cellular machinery to begin transcribing the nearby gene into a form that the cell will translate into a protein.

By causing a cell to make a particular protein, 1,25D alters cellular function, and this ability to trigger gene activity in different cells is the basis of vitamin D’s widespread physiological effects. Because D is a substance manufactured in one tissue and circulates through the body influencing many other tissues, it is also technically a hormone. In fact, the VDR belongs to a family of proteins known as nuclear receptors that respond to powerful steroidal hormones such as estrogen and testosterone.

At least 1,000 different genes are believed to be regulated by 1,25D, including several involved in the body’s calcium processing that account for D’s well-known role in bone formation. Over the past two decades, however, scientists have identified many other genes influenced by vitamin D activity in the body, including genes with critical roles in a variety of cellular defenses.

Fortification by D
Since the 1980s various lines of evidence have pointed to vitamin D’s protective effect against cancer. Many epidemiological studies have shown a strong inverse relation between exposure to sunlight and the incidence of certain types of cancer. Studies in animals and cell cultures have supported that association and helped to pinpoint the mechanisms that may be involved.

In a mouse model of head and neck cancer, for example, a compound called EB1089, which is a synthetic analogue of 1,25D, reduced tumor growth by 80 percent. Similar results have been attained in animal models of breast and prostate cancer. Identifying the genes activated by this synthetic version of D has helped explain these responses. Uncontrolled proliferation, or growth, is a hallmark of tumor cells, and EB1089 was shown to suppress the cells’ ability to multiply by altering the activity of a number of different genes. One gene ramped up by the compound—GADD45a—is well known for triggering growth arrest in normal cells whose DNA is damaged, thereby reducing their risk for becoming cancerous. In addition, EB1089 activates genes that direct tumor cells to become more differentiated, a mature state that limits a cell’s ability to proliferate.

Another dozen genes involved in a cell’s energy management and self-detoxification have also been linked to EB1089’s antitumor actions. That experimental compound, which was chemically designed to have 1,25D-like activity without causing toxic levels of calcium to build up in the bloodstream and body tissues, is one of several potential cancer therapies developed by pharmaceutical companies to harness vitamin D’s powerful antitumor properties.

Indeed, our laboratory group at McGill University was also investigating D’s cancer-related actions in 2004 when we inadvertently hit on a completely different form of physiological defense governed by 1,25D. Many of the genes regulated by vitamin D have been discovered in recent years by scientists scanning parts of the human genome, looking for vitamin D response elements (VDREs)—the distinctive sequences of DNA code that lie adjacent to genes, to which the VDR-RXR protein complex binds. In collaboration with Sylvie Mader of the University of Montreal, we used a computer algorithm designed to scan the entire genome, seeking out VDREs and mapping their positions relative to nearby genes.

Although these mapping studies did help us to better understand some of the anticancer actions of vitamin D, they also revealed VDREs lying close to two genes that encode antimicrobial peptides called cathelicidin and defensin beta 2. These small proteins act as natural antibiotics against a wide spectrum of bacteria, viruses and fungi. We pursued this lead with studies in cultured human cells and found that exposure to 1,25D caused a relatively modest increase in the cells’ manufacture of the defensin beta 2 peptide. But in a number of different cell types—including immune system cells and keratinocytes—the rise in cathelicidin production was dramatic. We next demonstrated that immune cells treated with 1,25D, when exposed to pathogenic bacteria, released factors—presumably cathelicidin—that killed off the bacteria.

Philip Liu and Robert Modlin of the University of California, Los Angeles, and their collaborators substantially advanced this line of investigation last year by showing that human immune cells respond to bacterial cell walls by manufacturing both VDR proteins and the enzyme that converts circulating 25D into the biologically active 1,25D. In the group’s experiments, these events induced the immune cells to start producing cathelicidin and to demonstrate antimicrobial activity against a variety of bacteria, including one that is perhaps the most intriguing: Mycobacterium tuberculosis. Thus, for the first time, the group revealed a plausible basis for the mysterious efficacy of the tuberculosis sunshine cure: the sun-soaked convalescents’ vitamin D boost could have provided their immune cells with the raw material needed to generate a natural antibiotic that fought off the TB bacteria.

As gaps in our understanding of vitamin D physiology are filled in, researchers have come to appreciate that a number of D’s protective actions in the body might have evolved from functions originating at the molecule’s source, in the skin. The growth-arresting influence of 1,25D on cancer cells makes sense in this light because excess UVB exposure is known to damage the DNA of skin cells, which can lead them to become cancerous. Some have also speculated that the antimicrobial response regulated by vitamin D is an adaptation that might have evolved to compensate for D’s role in suppressing certain other immune system reactions—specifically, those that lead to excessive inflammation. As many of us know too well from experience, excessive UVB exposure causes sun­­burned skin, which at the tissue level results in fluid buildup and inflammation. Although a limited amount of inflammation is a beneficial mechanism for wound healing and helps the immune system fight off infection, too much inflammation causes its own havoc.

Perhaps not surprisingly, then, an impressive body of work now shows that 1,25D also acts as an anti-inflammatory agent that functions by influencing immune cell interactions. For example, different subtypes of immune cells communicate by secreting factors called cytokines to initiate a particular type of immune response. Vitamin D has been shown to repress exaggerated inflammatory responses by inhibiting that cytokine cross talk.

Direct evidence of vitamin D’s natural role in preventing inflammation came first from animal experiments in the early 1990s, which showed that mice treated with 1,25D were protected from the inflammation normally associated with wounds and the chemical irritant dinitrobenzene, whereas vitamin D–deficient mice were hypersensitive to those same insults. This immune-suppressing function of vitamin D immediately suggested a range of new therapeutic possibilities for using vitamin D or its analogues in the control of autoimmune diseases thought to be caused by overactive cytokine responses, such as autoimmune diabetes, multiple sclerosis (MS) and inflammatory bowel disease.

Since that time, scientists have realized that many cell types, including immune cells, are capable of using circulating 1,25D and of converting circulating 25D to the active form of the vitamin, confirming that the anti-inflammatory actions of 1,25D are not restricted to skin cells nor simply to the context of sunburn.

Epidemic Deficiency?
Recognition that 1,25D has a broad range of biological activities far beyond its role in calcium homeostasis has thrown into sharp relief a large body of epidemiological evidence that low vitamin D levels correlate strongly with certain types of disease, among them cancers, autoimmune conditions and even infectious diseases, such as influenza, as well as with seasonal variations in illness rates. In addition, many of the noted physiological responses to vitamin D seen both in the laboratory and in clinical studies are optimized only when circulating concentrations of 25D are higher than is typical in many populations. Members of the vitamin D research community are therefore coming to a widespread consensus that substantial numbers of people in temperate regions of the world have levels of vitamin D that are well below optimal concentrations for health, particularly during winter months.

UVB light penetrates the atmosphere more directly in the tropics than in more temperate regions of the planet, which receive substantial amounts of it only during the summer. Because most people obtain vitamin D mainly through UVB exposure, circulating 25D levels in populations generally diminish with increasing latitude, although variations at a given latitude do arise because of differing ethnicities and diets, as well as variations in local climate and elevation. Consistent with vitamin D’s observed gene-regulatory activities, a clear association is seen between increasing latitude and increased risk of several illnesses, most conspicuously autoimmune diseases such as MS.

A chronic progressive illness, MS is caused by immune cell assaults on the protective myelin sheath that surrounds nerve fibers of the central nervous system. Its incidence is significantly higher in areas farthest from the equator in North America, Europe and Australia, and convincing evidence suggests that this pattern results from decreased UVB exposure. Disease progression and symptom flare-ups in MS sufferers also display well-established seasonal variations, with the highest disease activity in the spring (when circulating 25D levels would be lowest following the winter) and the least disease activity in the fall, after the summertime boost of D3. For example, scientists at the University of Southern California found an inverse relation among 79 pairs of identical twins between increased sun exposure during childhood and a lifetime risk of developing MS. The twins who spent more time outdoors as children had as much as 57 percent lower risk of developing the condition.

Similar patterns of risk for illness have been documented for autoimmune diabetes and for Crohn’s disease, an inflammatory autoimmune intestinal condition, as well as for certain types of malignancy. Population rates of cancers of the bladder, breast, colon, ovary and rectum increase twofold from south to north in the U.S., for instance.

In addition to the many studies correlating sun exposure with disease incidence, recent investigations have made similar connections between disease risk and direct measurements of circulating 25D concentrations in blood serum. An enormous survey by researchers at the Harvard School of Public Health looked at the stored serum samples of some seven million U.S. Army and Navy personnel as well as their health records to see which individuals had developed MS between 1992 and 2004. The researchers found a significantly lower risk of later developing the disease in the group with high serum 25D levels at the time the sample was taken. Soldiers with serum 25D concentrations above 40 nanograms per milliliter had a 62 percent lower risk than the soldiers whose concentrations were 25 ng/ml or below.

Measuring circulating levels of 25D is the usual method of gauging vitamin D availability in the body. Generally agreed on health standards, based largely on bone-forming needs, hold circulating 25D levels of 30 to 45 ng/ml to be minimally sufficient. Serum vitamin D concentrations below between 21 and 29 ng/ml are considered insufficient and often accompanied by decreased bone density. Some symptoms of rickets may appear when concentrations fall below 20 ng/ml, and the risk of colon cancer rises.

Such low concentrations are unfortunately all too common, especially in winter. In February and March of 2005, for example, a survey of 420 healthy females across northern Europe—in Denmark (Copenhagen: 55° latitude), Finland (Helsinki: 60°), Ireland (Cork: 52°) and Poland (Warsaw: 52°)—found that 92 percent of adolescent girls in these countries had 25D levels less than 20 ng/ml and that 37 percent of the girls were severely deficient, with 25D levels of less than 10 ng/ml. Among the older women tested, 37 percent were found to be vitamin D deficient and 17 percent were severely deficient.

Beyond latitude, several factors can contribute to vitamin D deficiency, and primary among these is race. White skin synthesizes vitamin D six times faster than dark skin because higher levels of melanin in darker skin block UV penetration [see “Skin Deep,” by Nina G. Jablonski and George Chaplin; Scientific American, October 2002]. As a result, African-Americans generally have levels of 25D that are approximately half those of whites in the U.S. In fact, data gathered for the U.S. National Health and Nutrition Examination Survey showed that 42 percent of African-American women tested were seriously 25D deficient, with serum concentrations of less than 15 ng/ml.

Increased public awareness that excessive exposure to sunlight causes skin damage is undoubtedly contributing to vitamin D deficiency as well. When properly applied, topical sunscreens reduce vitamin D produced in the skin by more than 98 percent. Enough vitamin D for good health can be synthesized in skin with sun exposure that might produce at most a slight pinkness, however. For most fair- and medium-skinned people in North America, this takes five to 15 minutes of sunlight between 10:00 A.M. and 3:00 P.M. during the summertime.

Vitamin D supplements could address the high prevalence of vitamin D deficiency in temperate zones, but how much people should take is still a subject of debate. The American Academy of Pediatrics recommends a minimum daily intake (RDI) of 200 international units (IU) for children, which many researchers have argued is suboptimal, even for rickets prevention. The RDI for adults in North America and Europe currently ranges between 200 IU and 600 IU, depending on age. After reviewing multiple studies comparing vitamin D intake and the serum concentrations of 25D produced, Harvard School of Public Health researchers and others concluded last year that the current RDIs are inadequate. They suggested that no less than half of U.S. adults needed to consume at least 1,000 IU of vitamin D3 daily to raise their serum 25D concentrations to the minimum healthy level of 30 ng/ml. No rule of thumb exists for calculating the serum 25D levels generated by supplements, because individual responses can vary and may depend in part on the extent of deficiency. A study of pregnant women showed, for example, that daily doses of 6,400 IU raised serum 25D levels dramatically until they reached about 40 ng/ml and then leveled off. Vitamin D2 has also been found to be less effective than D3 at raising and sustaining serum 25D concentrations over time.

Toxic vitamin D overdose through supplementation is certainly possible, although it is generally seen when doses of 40,000 IU or more of D have been taken daily for an extended period. Sunshine-induced vitamin D toxicity has never been observed, however. To put this in perspective, an adult woman with white skin exposed to summer sun while wearing a bikini generates about 10,000 IU of vitamin D in 15 to 20 minutes. Longer exposures do not generate higher amounts of vitamin D, because UVB light also degrades the vitamin, preventing too much of it from building up in the skin.

Accumulating evidence suggests that the subtle and longer-term effects of even slight vitamin D deficiency may be multifold and manifested later in life, in the form of increased frequency of bone fractures and enhanced susceptibility to infection and autoimmune diseases, as well as elevated frequencies of certain cancers. The research strongly implies that at the very least the general public would benefit substantially from greater awareness of the broad physiological benefits of vitamin D, a sound medical consensus on sensible sun exposure and a clear indication of optimal recommended daily intakes of vitamin D from dietary sources.

Particles Favor Chaos Over Calm

red blood cells in bloodstream
Blood work. Particles floating in a fluid--like blood cells--appear to move across the fluid currents, rather than simply being carried along, even at low concentrations.

Researchers have simultaneously observed the flow of both the liquid and solid components of a colloid--a fluid-particle mix akin to blood or contaminated ground water. The team used an MRI-like imaging system and found a surprise: even in slowly flowing, dilute colloids, the particles refuse to remain on purely parallel paths, like calm drivers on a highway. Instead, they change lanes erratically, as the researchers report in the 14 December Physical Review Letters. The new insights should improve researchers' understanding of flows in many kinds of colloids in biology and industry.

For high concentrations and flow speeds, particles in a colloid bump into each other frequently, leading to chaotic flow of the particles. But for a slow, dilute colloid flowing through a tube, researchers have thought that each particle remains on the fluid's local streamline--moving faster in the middle, slower near the edges--literally going with the flow. Now Joseph Seymour and Sarah Codd of Montana State University in Bozeman and their colleagues have challenged this assumption by independently measuring the liquid and particle flows. They used 2.5-micron-diameter oil-filled beads as their colloid particles because the oil can be tracked with the same MRI-type system that can measure the water flow surrounding them.

The team pumped their colloid--about 10% beads by volume--through a glass tube about the size of a pencil lead. They applied 3.5-millisecond-long magnetic field pulses whose strength varied with position. According to a standard nuclear magnetic resonance (NMR) technique, the different field strengths cause protons to emit radio waves at different frequencies, providing information on their positions. And the oil frequencies are easy to separate from the water frequencies. The team used sequences of field pulses to characterize the motion of the particles and the water.

Then came their NMR trick: A sequence of four pulses, where two pulses have the reverse field directions from the other two, should cancel the NMR effects of ordinary particle flow along streamlines. If each of six lanes of car traffic has a different speed, this sequence effectively starts cars at a starting line, allows them to drive for a fixed time, and then forces all of them to reverse direction at the same speeds and for the same time period. If the cars don't end up synchronized at the starting line, you know that someone wasn't following their speed limit. When observing for more than 100 milliseconds, Seymour and his colleagues were surprised to find exactly this result--additional particle diffusion not accounted for if they assumed that particles remained in their lanes. And the discrepancy grew as they increased the observation time--a result that meets the mathematical definition for a chaotic system.

Seymour and Codd's team concluded that interactions between particles must be more important than previously thought, and they are leading to frequent "lane changing" in the flow. "The simple models we've been using are probably not capturing the transport correctly," says Seymour. "In these dilute colloids, maybe these many-body interactions that we have traditionally associated with concentrated suspensions have applicability in the less concentrated ones."

The Montana team specifically chose bead sizes to mimic one important colloid: human blood. Seymour believes this research will have an impact on microfluidic devices and biosensors for blood. For now though, the basic science behind these flows is challenge enough. "These problems turn out to be very hard," says Michael Brenner of Harvard University. He says studies of colloid physics go all the way back to Einstein's seminal 1905 paper on the topic. "This is research [Einstein] would probably appreciate."

Calendar
03 2024/04 05
S M T W T F S
1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30
Timepiece
タグホイヤー フォーミュラー1 ドリームキャンペーン
Blog Plus
SEO / RSS
Podcast
by PODCAST-BP
New TB
Bar Code
Data Retrieval
Oldest Articles
(09/30)
(09/30)
(09/30)
(09/30)
(09/30)
Photo Index
Reference
Latina




RSS Reader
無料RSSブログパーツ
Misc.
◆BBS


◆Chat


◆Micro TV


Maps



顔文字教室




Copyright © Info All Rights Reserved.
Powered by NinjaBlog
Graphics by 写真素材Kun * Material by Gingham * Template by Kaie
忍者ブログ [PR]